Bristol-Myers Squibb Co. said the Japanese Ministry of Health, Labor, and Welfare has approved Opdivo (nivolumab) for unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy.
In this episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher of The Cancer Letter, Jacquelyn Cobb, managing editor, discuss the Sept. 23 meeting of the FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee, during which the panel voted in favor of Galleri, the multi-cancer detection test from GRAIL Inc., to become the first multi-cancer detection test to receive regulatory approval.
